The Centers for Medicare and Medicaid Services is releasing new details about how people can get drugs that may slow the progression of Alzheimer’s disease covered by Medicare.

If the Food and Drug Administration grants traditional approval, then Medicare will cover the drug in what CMS deems “appropriate” settings –  that also support the collection of real-world information to study the usefulness of these drugs for people with Medicare.